Melanoma: all 3,073 studies
Page 14 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursActive, not recruitingNCT06305247Phase 1/2
- NM32-2668 in Adult Patients With Selected Advanced Solid TumorsTerminatedNCT06299163Phase 1
- Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the EsophagusCompletedNCT06291753
- Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayTerminatedNCT06287463Phase 1
- A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1
- YASU Research Registry: For Young Adults With CancerTerminatedNCT06275854
- Study of IK-595 in RAS- or RAF-altered Advanced TumorsTerminatedNCT06270082Phase 1
- Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic MelanomaCompletedNCT06251934
- ctDNA for Early Detection of Recurrence in MelanomaActive, not recruitingNCT06246227
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid TumorsActive, not recruitingNCT06237881Phase 1/2
- A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsCompletedNCT06208124Phase 1/2
- Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma PatientsActive, not recruitingNCT06207747Not applicable
- A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaActive, not recruitingNCT06190951Phase 2
- Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable MelanomaWithdrawnNCT06190249Phase 1
- Holistic Needs Assessments in Patients With MelanomaCompletedNCT06189261
- CALM: Managing Distress in Malignant Brain CancerCompletedNCT06180460Not applicable
- Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer SurvivorsCompletedNCT06171945Not applicable
- A Study of ASP1012 in Adults With Solid TumorsTerminatedNCT06171178Phase 1
- A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With MelanomaCompletedNCT06163170
- A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaCompletedNCT06153238Phase 1
- Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma PatientsCompletedNCT06152367Phase 1/2
- Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic MelanomaCompletedNCT06151847Phase 2
- Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment DiscontinuationActive, not recruitingNCT06146920Not applicable
- A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1
- A Study of GC101 TIL in Advanced Melanoma (BZ)CompletedNCT06120712Phase 1/2
- Study of DF6215 in Patients With Advanced Solid TumorsCompletedNCT06108479Phase 1
- Compassionate Use of VidutolimodNo longer availableNCT06063746
- A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaActive, not recruitingNCT06054555Phase 3
- Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesTerminatedNCT06052852Phase 1
- Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented TumorsCompletedNCT06046144
- Survival Monitoring in Russian Cancer RegistriesActive, not recruitingNCT06043947
- Intratumoral PH-762 for Cutaneous CarcinomaCompletedNCT06014086Phase 1
- Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingNCT06008977Not applicable
- LifeChamps Feasibility StudyActive, not recruitingNCT05990634Not applicable
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingNCT05987332Phase 2/3
- Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaActive, not recruitingNCT05986331Phase 3
- Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma PatientsCompletedNCT05984615
- Safety and Avoidance of Futile Excisions Through Skin Tele-triageCompletedNCT05982600
- A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsActive, not recruitingNCT05973487Phase 1
- A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)Active, not recruitingNCT05933577Phase 3
- A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2
- GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05913388Phase 2
- A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaActive, not recruitingNCT05912244Phase 2
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsActive, not recruitingNCT05907304Phase 1
- A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaCompletedNCT05907122Phase 3
- Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid TumorsActive, not recruitingNCT05902520Phase 1
- Head and Neck Melanoma; Access to Staging and Surgical TreatmentCompletedNCT05900102
- A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
- Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of MelanomaCompletedNCT05874817
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsCompletedNCT05864144Phase 1/2
- Analyzing Clinical Outcomes and Genomic Data of American Indian Patient PopulationActive, not recruitingNCT05863052
- Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
- Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + BinimetinibTerminatedNCT05848219
- The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III MelanomaStatus unknownNCT05827770Phase 2
- Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial CarcinomaStatus unknownNCT05823246Phase 2
- Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision TherapeuticsTerminatedNCT05819827
- TRAQinform Assessment of Immunotherapy ResponseCompletedNCT05819255
- Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma; a Pilot StudyCompletedNCT05817149
- Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma PatientsCompletedNCT05806268
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05789069Phase 1
- Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05783882Phase 3
- T3011 in Combination With Cobimetinib in Patients With Advanced MelanomaSuspendedNCT05756556Phase 2
- A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaActive, not recruitingNCT05751928Phase 3
- Multicenter Tissue Registry in MelanomaStatus unknownNCT05750511
- Analysis of Circulating Exosomes in Melanoma PatientsStatus unknownNCT05744076
- Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung CancerCompletedNCT05740501
- Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)Active, not recruitingNCT05736523
- A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaActive, not recruitingNCT05732805Phase 3
- Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the LungWithdrawnNCT05717140Phase 1
- Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of MelanomaCompletedNCT05714371
- Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology ExpertsCompletedNCT05712551
- IMM60 and Pembrolizumab in Melanoma and NSCLCTerminatedNCT05709821Phase 1/2
- A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)CompletedNCT05708950Phase 1/2
- Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor TherapyCompletedNCT05707286
- Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesCompletedNCT05704933Early Phase 1
- Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving ImmunotherapyActive, not recruitingNCT05703269Not applicable
- XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor TherapyTerminatedNCT05695898Phase 1
- Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal MelanomaWithdrawnNCT05677373Phase 1/2
- CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain MetastasesSuspendedNCT05669352Phase 1/2
- A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsCompletedNCT05668585Phase 1
- A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.Active, not recruitingNCT05661955Phase 1/2
- App Teaches Doctors to Diagnose Skin CancerCompletedNCT05661370Not applicable
- A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsActive, not recruitingNCT05653882Phase 1
- Mentored Community Gardening for Individuals With Skin CancerCompletedNCT05648604Not applicable
- The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant MelanomaStatus unknownNCT05645484
- A Study of LN-144 in People With Metastatic Melanoma to the BrainActive, not recruitingNCT05640193Phase 1
- Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory MelanomaCompletedNCT05628883Phase 1
- Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma PatientsCompletedNCT05615883Not applicable
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid TumorsActive, not recruitingNCT05614102Phase 1
- Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor BurdenCompletedNCT05611229
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryActive, not recruitingNCT05608291Phase 3
- Intrathecal Double Checkpoint InhibitionActive, not recruitingNCT05598853Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT05581004Phase 1
- Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced MalignanciesCompletedNCT05577182Phase 1
- A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT05576077Phase 1
- A Study to Investigate LYL845 in Adults With Solid TumorsTerminatedNCT05573035Phase 1
- A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous MelanomaWithdrawnNCT05572463Phase 1/2
- A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsTerminatedNCT05571839Phase 1
- MR Lymphography and Magnetic Sentinel Lymph Node Biopsy in Melanoma PatientsStatus unknownNCT05569707Not applicable
- A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma PatientsWithdrawnNCT05561491Phase 2